The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: Okay. [Music in my ears], I'm a stock guy. You're a stock guy Let's talk a little bit more about the stock. From where I sit. Some of what you just laid
out is certainly on the right path. You have stabilized the top line, you have cut the costs, you have reprioritized certain pipeline programs yet the
shares themselves, the stock is certainly near its all-time lows or most recent lows.
What doesn't resonate with investors when you talk to folks are either our conference or others, what are they reflecting back to you?
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: For those of us who aren't on the inside what was left on the cutting room floor with regard to the $400 million in cost savings under Fit-for-Growth
is there anything that you don't have capability wise? You've talked about supporting these launches, which is a capability. What can you no longer
do?
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: Chunk, let's go deeper into what can be your thoughts about the reset that happens happened there or are we done with the reset or expectations
appropriate? And you've also spoken to is sort of a steady growth curve as opposed to any sort of accelerating growth in the future? Why or what
shouldn't we be a little bit more optimism acceleration?
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: Well, absent that inflection and this launch has had its challenges. As you just laid out, Chunk absent that inflection. Of course, investors can't be
confident that we're going to get to here, right?
You mentioned earlier that is still going to be a very important drug. You think this is a very large market. You think we may end up in the same
place just through a different path. What do you think is the most important or most for you as somebody sticks or things all the time about what
can be, what's the best ray of hope, the best beacon of light to think at the end of the day. This is a multibillion dollar drug.
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: Okay. We've got another drug in the marketplace to some of Donanemab, Lilly? Is it too early to say what you're seeing there or what are you seeing
from?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 18, 2024 / 5:20PM, BIIB.OQ - Biogen Inc at Cantor Global Healthcare Conference
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: Makes lot of sense. One, headwind that you've had to face in the last couple of months is in Europe where you had a negative CHMP. So tell us
where we are in the process in terms of hoping to reverse that?
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: You've already asked for the re-examination. So that clock has started -- re-exam when the 60 days?
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: That's right.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
SEPTEMBER 18, 2024 / 5:20PM, BIIB.OQ - Biogen Inc at Cantor Global Healthcare Conference
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: Investor standpoint you're committed to just announcing that decision when that happens.
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: That's right. Thank you for that. Maybe just give us an update and Chuck on the subcu lay the land for us there and what's --
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: With the subcu induction, we're still talking bioequivalence. So within a range -- at the higher or lower end of that range, that's running at a higher
level. And now you'll be going to. So it's not going to be dramatically less than that?
Question: Eric Schmidt - Cantor Fitzgerald & Co., Inc. - Analyst
: Okay, great. So let's shift then to Skyclarys. Seen a good initial launch. And I don't see even in the last couple of quarters, somewhat steady patient
by patient growth, quarter-by-quarter growth. Maybe just talk about the US And then where are we with the ex-US launch and sort of historically,
| 
